Business Context and Reporting Period
This Form 8-K filing by Inogen, Inc. (Delaware) covers events occurring on August 3, 2015, with the report dated August 6, 2015. The filing addresses changes to the Board of Directors, specifically the resignation of one director and the appointment of another.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance changes and director compensation arrangements.
Material Changes
- Resignation: Timothy Petersen resigned as a member of the Board of Directors, the Compensation, Nominating, and Governance Committee, and the Audit Committee, effective immediately on August 3, 2015. The resignation was not due to any disagreement with the Company.
- Appointment: R. Scott Greer was appointed to the Board of Directors as a Class I director and as a member of the Audit Committee, effective immediately on August 3, 2015.
- Committee Adjustment: The Compensation, Nominating, and Governance Committee was reduced by one member following Mr. Petersen's departure.
Guidance, Outlook, and Compensation Details
The filing contains no guidance, outlook, or management commentary regarding future business operations. It details the compensation package for the newly appointed director, Mr. Greer, under the Company's standard program for non-employee directors:
- Base Retainer: $35,000 annually.
- Committee Retainers: Additional retainers apply for committee chairpersons ($20,000 for Audit Committee Chair; $15,000 for Compensation Committee Chair).
- Initial Equity Award: Option to purchase 6,666 shares of common stock, vesting in 24 monthly installments.
- Annual Equity Awards: Eligible directors receive options for 6,666 shares annually, with additional shares for committee chairpersons (1,666 for Audit Chair; 1,166 for Compensation Chair).
- Expenses: Reimbursement for all reasonable expenses.
Investor Verification Checklist
- Verify the biographical background and potential conflicts of interest for new director R. Scott Greer, given his extensive history in biotechnology and venture capital.
- Confirm the impact of the Board composition change on the Audit Committee's independence and expertise.
- Review the attached press release (Exhibit 99.1) for any additional context regarding the leadership transition.
- Note that this filing does not contain financial results; refer to the most recent 10-Q or 10-K for financial performance data.